Corneal endothelial cell regeneration

Corneal endothelial cell regeneration is a physiological and therapeutic process aimed at restoring the monolayer of hexagonal cells on the posterior surface of the cornea. In humans, these cells are arrested in the G1 phase of the cell cycle and do not naturally proliferate in vivo, leading to permanent vision loss if the cell density falls below a critical threshold due to disease or trauma. Therapeutic strategies primarily target the Rho-associated protein kinase (ROCK) signaling pathway to bypass this mitotic arrest and stimulate cell division. By promoting regeneration, clinicians can treat conditions like Fuchs' endothelial corneal dystrophy and bullous keratopathy without requiring full-thickness corneal transplants. Current pharmacological approaches include the use of topical ROCK inhibitors such as Ripasudil, which facilitate the migration and proliferation of remaining healthy cells to cover denuded areas of the Descemet membrane. This process is essential for maintaining the cornea's dehydrated state and optical clarity through the active 'pump-and-leak' mechanism.

Other names

HCEC regenerationCorneal endothelial wound healingRestoration of corneal endothelial density

Pharmacological intervention typically involves Rho-associated protein kinase (ROCK) inhibition, which promotes corneal endothelial cell proliferation by upregulating cyclin D and downregulating p27kip1, while also enhancing cell adhesion and reducing apoptosis.